Article

First-line therapy: Latanoprost approved for glaucoma use in Europe

Peapack, NJ-Regulatory authorities governing Europe's Mutual Recognition Process have approved the use of latanoprost ophthalmic solution (Xalatan) as a first-line treatment for lowering IOP in patients with open-angle glaucoma and ocular hypertension.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Related Content
(Image credit: AdobeStock/Vitalii Vodolazskyi) Yale researchers identify corneal ulcer pathogens by testing tears
July 1st 2025

Yale researchers identify corneal ulcer pathogens by testing tears

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

HLB Therapeutics misses primary end point in phase 3 SEER-3 trial of RGN-259
July 1st 2025

HLB Therapeutics misses primary end point in phase 3 SEER-3 trial of RGN-259

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Most patients support AI in health care if it means more time with doctors
June 30th 2025

Most patients support AI in health care if it means more time with doctors

Nanoscope Therapeutics forms Vision Advisory Committee
June 30th 2025

Nanoscope Therapeutics forms Vision Advisory Committee

© 2025 MJH Life Sciences

All rights reserved.